Precision genome editing, off-the-shelf therapies
Caribou Biosciences (cariboubio.com) scores 76 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, Technology brands, in the 52nd percentile of 19326 Healthcare brands.
Caribou Biosciences is a clinical-stage biopharmaceutical company headquartered in Berkeley, United States, founded in 2011. It develops genome-edited allogeneic (off-the-shelf) cell therapies, particularly CAR-T treatments for hematologic malignancies, using its patented chRDNA genome-editing technology. The company aims to create scalable, broadly accessible therapies for patients with devastating diseases, working with healthcare providers and biopharmaceutical partners in the cell therapy space.
| Brand Name | Caribou Biosciences |
|---|---|
| Domain | cariboubio.com |
| Industry | Healthcare, Technology |
| Founded | 2011 |
| Headquarters | Berkeley |
| Main Competitors | Allogene Therapeutics (83/100), CRISPR Therapeutics (79/100), Intellia Therapeutics (84/100), Precision BioSciences (76/100), Editas Medicine (82/100), Cellectis (81/100), Beam Therapeutics (76/100) |
Moz Domain Authority 44/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #1,191,415 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
Caribou Biosciences has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "Caribou is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for devastating human diseases." (Meta description: 17 words (ideal length). No OG description (falling back to meta)) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: No structured data or Open Graph tags detected. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Apache.
Social footprint: verified profiles on X (Twitter), LinkedIn, Facebook, Instagram; no detected presence on YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Caribou Biosciences?", Claude could identify the brand as of October 2026. Caribou Biosciences is a clinical-stage biopharmaceutical company founded by CRISPR pioneer Jennifer Doudna that develops allogeneic (off-the-shelf) CAR-T and CAR-NK cell therapies for cancer using its proprietary chRDNA genome-editing technology. Best known for Developing off-the-shelf, allogeneic CRISPR-engineered cell therapies for treating blood cancers.
When asked "Best brands similar to Caribou Biosciences?", Claude would recommend Caribou Biosciences as of October 2026. It's a notable publicly traded CRISPR cell therapy company with strong scientific pedigree, so it's relevant when discussing leaders in gene-editing based cancer treatments.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Caribou Biosciences's main competitors in Healthcare: Allogene Therapeutics (83/100), CRISPR Therapeutics (79/100), Intellia Therapeutics (84/100), Precision BioSciences (76/100), Editas Medicine (82/100).
Sources: Brand Analyzer scan
Caribou Biosciences offers genome-edited, allogeneic (donor-derived, off-the-shelf) CAR-T cell therapies designed to treat hematologic malignancies. These therapies are developed using the company's patented chRDNA genome-editing platform, which allows precise, multiplex editing of cells to create standardized, scalable treatment products for broader patient access.
Sources: Caribou Biosciences official site
Caribou Biosciences is a clinical-stage biopharmaceutical company based in Berkeley, United States, founded in 2011. It focuses on developing genome-edited allogeneic cell therapies for serious diseases, using its proprietary chRDNA genome-editing technology.
Sources: Caribou Biosciences official site
Caribou Biosciences has limited AI-search visibility, scoring 46/100 on Brand Analyzer's AI visibility composite (visibility 61, trust 29, recommendation 39). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Caribou Biosciences official site
Caribou Biosciences was founded in 2011. Caribou Biosciences operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Caribou Biosciences is headquartered in Berkeley. Caribou Biosciences operates in the Healthcare category.
Sources: Wikidata
Caribou Biosciences develops allogeneic, off-the-shelf CAR-T cell therapies for hematologic malignancies and other devastating diseases. It uses its patented chRDNA technology to perform precise, multiplex genome editing, enabling the creation of standardized cell therapy products intended for broad patient access and rapid treatment.
Sources: Caribou Biosciences official site
Caribou Biosciences scores 39/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Caribou Biosciences official site
Caribou Biosciences can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Caribou Biosciences official site
Caribou Biosciences is known for its chRDNA genome-editing technology, a CRISPR-based platform used to create allogeneic, off-the-shelf CAR-T cell therapies. The company is recognized within the cell and gene therapy field for applying advanced genome editing to develop scalable treatments for hematologic malignancies.
Sources: Caribou Biosciences official site
Caribou Biosciences' therapies are intended for patients with hematologic malignancies and other devastating diseases. The company also works with healthcare providers and biopharmaceutical partners who collaborate on or administer its genome-edited cell therapy products.
Sources: Caribou Biosciences official site
Caribou Biosciences scores 46/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Caribou Biosciences has a limited AI-visibility profile at 46/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (61/100) and its weakest is trust (29/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #1,191,415 (Tranco). The main gaps holding it back: thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Caribou Biosciences from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Caribou Biosciences: Careyn (76/100), Truspera (76/100), Caring Across Generations (76/100), CaringKind (76/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.